知识与财富的链接
目的探讨经导管直接溶栓（CDT）治疗下肢深静脉血栓中尿激酶的合理用量。方法将拟接受CDT的90例DVT患者随机分为3组：A组用小剂量尿激酶溶栓（每日用量〈40万U）,B组用中等剂量（每日用量40万～80万U）,C组用大剂量（每日用量〉80万U）进行溶栓治疗。比较3组的溶栓效果、溶栓时间及出血情况。结果3组溶栓疗效差异有统计学意义（Hc=15．09,P〈O．05）,A组与B组疗效差异有统计学意义（t=1．99,P〈0．05）。3组溶栓时间差异有统计学意义（F=4．92,P〈0．05）。各组出血发生率差异无统计学意义（x^2=2．96,P〉0．05）,C组出血程度最重。结论CDT治疗DVT安全有效,每日尿激酶用量在40万U～80万U时溶栓疗效好,且出血发生率低。
Objective To analyze the reasonable dosage of urokinase in patients with lower limb deep vein thrombosis （DVT） treated with catheter-directed thrombolysis （CDT）. Methods Ninety patients with DVT who would be treated with CDT were randomly divided into three groups. Patients in group A were given with low dose of urokinase （〈 400 000 U per day, in group B with medium dose （400 000 U--800 000 U per day）, while group C with larger dose uroki- nase （〉800 000 U per day）. The thrombolysis effect, thrombolytic treatment time and hemorrhage situation were compared among the three groups. Results The thrombolytic therapy effect were different among three groups （He = 15.09, P 〈0. 05）. The effect were different between group A and group B （t= 1.99, P〈0. 05）. Thrombolytic time difference had statistical significance （F= 4. 92, P〈0.05）. No statistical significance of hemorrhage was found among three groups （X^2= 2.96, P〉0.05）. Hemorrhage of group C was the most serious. Conclusion CDT for treatment of DVT is safe and effective. Using urokinase 400 000--800 000 U per day, the thrombolytic effect is good, and the rate of hemorrhage remains low.